Moderna, Inc. $MRNA Shares Bought by Russell Investments Group Ltd.

Russell Investments Group Ltd. raised its holdings in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 18.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 531,893 shares of the company’s stock after buying an additional 84,445 shares during the quarter. Russell Investments Group Ltd. owned about 0.13% of Moderna worth $102,551,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in MRNA. Western Pacific Wealth Management LP purchased a new stake in shares of Moderna in the 3rd quarter valued at about $29,000. Allied Private Wealth LLC purchased a new position in shares of Moderna during the second quarter worth about $30,000. CENTRAL TRUST Co increased its position in shares of Moderna by 36.5% in the third quarter. CENTRAL TRUST Co now owns 172 shares of the company’s stock worth $33,000 after purchasing an additional 46 shares during the last quarter. Next Level Wealth Planning LLC bought a new position in shares of Moderna in the third quarter worth approximately $34,000. Finally, Archer Investment Corp purchased a new stake in Moderna in the second quarter valued at approximately $36,000. 75.33% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, insider Shannon Klinger sold 3,471 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the completion of the sale, the insider owned 74,129 shares of the company’s stock, valued at approximately $10,374,353.55. This represents a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James M. Mock sold 34,836 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the completion of the transaction, the chief financial officer owned 59,375 shares in the company, valued at $7,985,343.75. This represents a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 197,251 shares of company stock valued at $33,875,904 in the last ninety days. Company insiders own 10.80% of the company’s stock.

Moderna Price Performance

MRNA opened at $223.37 on Monday. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $280.80. The company has a current ratio of 3.62, a quick ratio of 3.47 and a debt-to-equity ratio of 0.52. The business’s 50-day moving average price is $201.67 and its 200-day moving average price is $96.41. The company has a market cap of $90.38 billion, a P/E ratio of -31.46 and a beta of 1.16.

Moderna (NASDAQ:MRNA – Get Free Report) last issued its earnings results on Friday, November 6th. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of ($1.10) by $1.48. Moderna had a negative return on equity of 25.79% and a negative net margin of 110.46%. The company had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $890.25 million. During the same period in the prior year, the business posted ($0.51) EPS. Moderna’s quarterly revenue was up 29.2% compared to the same quarter last year. On average, equities analysts expect that Moderna, Inc. will post -5.14 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on MRNA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Moderna in a research report on Wednesday, September 9th. Argus upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $180.00 price objective on the stock in a research report on Friday, August 28th. Loop Capital set a $135.00 price objective on shares of Moderna in a research report on Wednesday, August 19th. Evercore upped their target price on shares of Moderna from $50.00 to $80.00 in a research report on Thursday, October 8th. Finally, Deutsche Bank began coverage on Moderna in a research note on Friday, August 28th. They issued a “hold” rating and a $125.00 target price on the stock. Six research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat.com, Moderna has a consensus rating of “Hold” and an average price target of $113.75.

Get Our Latest Analysis on MRNA

About Moderna

(Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

Recommended Stories

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.